Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 4Phase 1/2 1

Status

Completed 4Terminated 1

Sponsor Class

NIH 2INDUSTRY 2OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 84Gastrointestinal 17CNS 11Head & Neck 9Genitourinary 6Gynecologic 5Tumor-Agnostic 4Thoracic 4Sarcoma 1Endocrine 1Dermatologic 1

Conditions

Ovarian Neoplasms 2Neoplasms 2Carcinoma, Ovarian Epithelial 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Recurrence 1Esophageal Neoplasms 1Endometrial Neoplasms 1

Interventions

Paclitaxel 233Carboplatin 217Bevacizumab 139Cisplatin 136pembrolizumab 89Gemcitabine 69olaparib 54Docetaxel 47Topotecan 44Radiotherapy 43liposomal doxorubicin 41Taxes 41niraparib 38Cyclophosphamide 36Doxorubicin 30Drug Therapy 29Letrozole 28Nivolumab 27Magnetic Resonance Spectroscopy 25Immunoglobulin G 25Disulfides 24Oxaliplatin 23Albumin-Bound Paclitaxel 23durvalumab 22apatinib 21Etoposide 21Brachytherapy 21lenvatinib 20camrelizumab 20Specimen Handling 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Lapatinib × Gynecologic × Clear all
NCT00096447 2019-07-24

Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
31 enrolled 13 charts
Gynecologic

Endometrial Neoplasms

NCT00113373 2019-07-24

Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer

National Cancer Institute (NCI)

Phase 2 Completed
28 enrolled 11 charts
Gynecologic

Carcinoma, Ovarian Epithelial

NCT00430781 2015-05-08

Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer

GlaxoSmithKline

Phase 2 Completed
228 enrolled 21 charts
Gynecologic

Uterine Cervical Neoplasms, Neoplasms, Recurrence

NCT00436644 2014-04-16

Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin

Mayo Clinic

Phase 2 Completed
18 enrolled 10 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00447226 2012-06-12

Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists

GlaxoSmithKline

Phase 2 Terminated
32 enrolled 10 charts
GastrointestinalGenitourinaryGynecologic

Urinary Bladder Neoplasms, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡